Posted at September 18, 2013 7:50 pm by Leleah Robinson
Government agencies, industry, and patient advocacy groups all agree that a patient-centered perspective is vital during the processes of drug development, clinical trials, benefit/risk assessment, and regulatory review. However, legal barriers and proprietary constraints complicate when patients can be brought to the table and integrate their input.
At the FDA’s annual Patient Network meeting, “Demystifying FDA: An Exploration in Drug Development”, there was a concerted effort among all stakeholders to increase collaboration. read more >
Most mornings, my commute is a 12-minute drive from my home in the hills above Danbury, Connecticut, to the nearby NORD offices. But Tuesday’s commute started early – 5:30 a.m. – with a train ride into New York City and a brisk walk up 42nd Street to the NASDAQ Marketplace in Times Square. read more >
Genetic biobanks, storage facilities for DNA, genetic data and tissue samples, are becoming more prevalent in the rare disease community. The information and samples can be made available to approved researchers for clinical studies, but unlike clinical trials, there is usually no personal benefit or follow-up provided to participants. read more >
In my role as NORD’s research grant program administrator, I’m in the unique position to frequently speak with many researchers. Whether they are applying for one of our scientific seed grants (“RFPs”), or asking if NORD has funding to study a particular rare condition – these conversations are always positive, always punctuated with enthusiasm. read more >